The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced it has received two nominations in the Fourth Annual Pharmaceutical Achievement Awards competition. CEO Victoria Hale was named a finalist for the Emerging Company Executive of the Year award and OneWorld Health was named a finalist in Global Healthcare Social Responsibility, both in the Pharmaceutical Business Category.

Finalists for the Fourth Annual Pharmaceutical Achievement Awards were designated through a comprehensive international nomination process and selected by a distinguished 35-member industry/academic executive review board. Categories range from Research and Development, Pharmaceutical Business and Pharmaceutical Marketing and consist of 18 awards. Winners will be announced on Aug. 8 during a gala ceremony in Boston, Massachusetts. The awards are sponsored by various industry groups, and medical and science media. A complete list of nominees and categories is available at www.pharmawards.com .

The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company, develops new, affordable medicines for infectious diseases that disproportionately affect people in the developing world, including visceral leishmaniasis, malaria, diarrhea and Chagas disease. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists that identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3) U.S. corporationcorporation(http://www.oneworldhealth.org/ ) ). Media resources are available at http://www.oneworldhealth.org/media/index.php .